On December 1, 2022, the Swiss Federal Office of Public Health published the changes that will occur to the Services Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The updates will enter into force on January 1, 2023, and they include the following:
- Minor changes in the Healthcare Benefit Ordinance (KLV/OPre), which relate to the provision of medical aids by chiropractitians, vaccines, and colon cancer screening;
- Changes in Annex 1 of the Healthcare Benefit Ordinance (list of explicitly evaluated services):
- Coverage of Evidence Development was extended for several services related to cell therapies (for up to four years);
- Two new services were added to the “Nuclear medicine” section;
- Changes in Annex 1a of the Healthcare Benefit Ordinance (outpatient-before-hospital services):
- New chapters for ophthalmology (cataract intervention), cardiology, urology, and orthopedics areas were added, with many new CHOP codes being included;
- Changes in Annex 2 of the Healthcare Benefit Ordinance (List of Tools and Appliances):
- New categories for medical aids for administration of drugs were introduced;
- Changes in Annex 3 of the Healthcare Benefit Ordinance (List of Analyses):
- Changes in conditions for the provision of various tests related to genetic and rare diseases;
- Three new tests for tumor diseases were introduced.
More details can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.